Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 11, 2004, Pages 1882-1888

  Lillo Le Louet A ^a   Boutouyrie, P ^a   Alhenc Gelas, M ^a   Le Beller, C ^a   Gautier, I ^a   Aiach, M ^a   Lasne, D ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Cardiopulmonary bypass; Clinical score; Early diagnosis; Platelet count; ROC curve

Indexed keywords

ARGATROBAN; DANAPAROID; HEPARIN; HIRUDIN; LEPIRUDIN;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MONITORING; DRUG SENSITIVITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SEPSIS; THROMBOCYTE COUNT; THROMBOSIS;

AGED; ANTIBODIES; CARDIOPULMONARY BYPASS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROBABILITY; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA;

EID: 13244282990     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00949.x     Document Type: Article

References (28)

1. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96: 1703-8.
2. Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99: 2530-6.
3. Bauer TL, Arepally G, Konkle BA, Mestichelli B, Shapiro SS, Cines DB, Poncz M, McNulty S, Amiral J, Hauck WW, Edie RN, Mannion JD. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997; 95: 1242-6.
4. Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998; 101 653-5.
5. Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac AM, Peynaud-Debayle E, Dreyfus M, Meyer D. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995; 73 21-8.
6. Singer RL, Mannion JD, Bauer TL, Armenti FR, Edie RN. Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass. Chest 1993; 104: 1436-40.
7. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003; 76: 638-48.
8. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106: 629-35.
9. Chong BH. Heparm-induced thrombocytopenia. J Thromb Haemost 2003; 1: 1471-8.
10. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002; 126: 1415-23.
11. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, Vondracek T. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129: 886-90.
12. Stephan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A. Thrombocytopenia in a surgical ICU. Chest 1999; 115: 1363-70.
13. Lecompte T, Stieltjes N, Shao-Kai L, Morel MC, Kaplan C, Samama MM. Heparin- and streptokinase-dependent platelet-activating immunoglobulin G: mechanism and diagnosis. Semin Thromb Hemost 1995; 21: 95-105.
14. Pouplard C, Amiral J, Borg JY, Vissac AM, Delahousse B, Gruel Y. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol 1997; 99: 273-80.
15. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2: 148-57.
16. Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999; 111: 700-6.
17. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30.
18. Bachelot-Loza C, Saffroy R, Lasne D, Chatellier G, Aiach M, Rendu F. Importance of the FcgammaRIIa-Arg/His-131 polymorphism in heparin-induced thrombocytopenia diagnosis. Thromb Haemost 1998; 79: 523-8.
19. Lasne D, Lillo-Le Louët A, Boutouyrie P, Kreft-Jaïs C, Aiach M. Early diagnosis of heparin-induced thrombocytopenia (HIT) in patients after cardiopulmonary bypass (CPB) through the platelet count profile. Thromb Haemost 2001; (Suppl.): P1933.
20. Pouplard C, May MA, Regina S, Maakaroun A, Fusciardi J, Gruel Y. Changes in the platelet count after cardiopulmonary bypass can efficiently predict the development of pathogenic heparin-dependent antibodies. Blood 2002; 100: 16a.
21. Walenga JM, Jeske WP, Fasanella AR, Wood JJ, Ahmad S, Bakhos M. Laboratory diagnosis of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 1999; 5 (Suppl. 1): S21-7.
22. Fohlen-Walter A, De Maistre E, Mulot A, Marchand-Arvier M, Lecompte T. Does negative heparin-platelet factor 4 enzyme-linked immunosorbent assay effectively exclude heparin-induced thrombocytopenia? J Thromb Haemost 2003; 1: 1844-5.
23. Eichler P, Raschke R, Lubenow N, Meyer O, Schwind P, Greinacher A. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 2002; 116: 887-91.
24. Tardy/Poncet B, Mahul P, Beraud AM, Favre JP, Tardy B, Guyotat D. Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome. Br J Haematol 1995; 90: 969-70.
25. Insler SR, Kraenzler EJ, Bartholomew JR, Kottke-Marchant K, Lytle B, Starr NJ. Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia. Anesthesiology 1997; 86: 495-8.
26. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Anti-hirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000; 96: 2373-8.
27. Westphal K, Martens S, Stroultal U, Matheis G, Lindhoff-Last E, Wimmer-Greinecker G, Lischke V. Heparin-induced thrombocytopenia type II: perioperative management using danaparoid in a coronary artery bypass patient with renal failure. Thorac Cardiovasc Surg 1997; 45: 318-20.
28. Nowak G, Bucha E, Goock T, Thieler H, Markwardt F. Pharmacology of r-hirudin in renal impairment. Thromb Res 1992; 66: 707-15.